>  Treat  >  Strategic Partnerships

Strategic Partnerships

Our global partnerships allow us to draw on both individual and collective expertise in scientific discoveries and drug development. We are proud to have participated in the following collaborations:


DEEP was a multi-year research project coordinated by the Consorzio per Valutazioni Biologiche e Farmacologiche organization in Italy, under the leadership of Prof. Adriana Ceci. The project included 32 recruiting centres in countries in Europe (Albania, Cyprus, Greece, Italy, Turkey, and the United Kingdom) and the Middle East (Egypt, Lebanon, Morocco, Qatar, and Tunisia), together with scientific partners from several European countries and ApoPharma. The project has met its aim to produce and evaluate a new oral liquid formulation of deferiprone suitable for pediatric use and to integrate the existing information on deferiprone use in iron overloaded pediatric patients.

FAIR PARK II is a major EU-funded research project investigating the effects of deferiprone on the progression of Parkinson's disease. The project will run for six years (2015 - 2020) and will involve numerous collaborators. Its full title is: "Conservative iron chelation as a disease-modifying strategy in Parkinson's disease: A multicentric, parallel group, placebo-controlled, randomized clinical trial of deferiprone."
It has been shown that there is a maldistribution of iron in the central nervous system of ALS patients. Iron accumulation, associated with a loss of motor neurons, may be associated with the signs of the disease (motor neuron death). Our collaboration with University Hospital Lille to investigate the safety and efficacy of an open label study for the treatment of ALS with deferiprone was completed in December 2016. A randomized double blind controlled study to assess the safety and efficacy of deferiprone in ALS, funded by the French government and further supported by ApoPharma is now being planned.

Recent findings suggest that high brain iron levels may be associated with Alzheimer's disease. Together with the National Health and Medicine Research Council of Australia, ApoPharma is supporting an investigation to determine if deferiprone, a drug that lowers brain iron levels, would slow the progression of Alzheimer's disease in its early stages.

For more information, please visit: National Collaborative Research Infrastructure Strategy of Australia

Two ApoPharma-sponsored studies in patients with a rare disorder involving brain iron overload were recently concluded. Neurodegeneration with Brain Iron Accumulation (NBIA) is a group of rare inherited movement disorders that usually begin in childhood, are relentlessly progressive, and cause severe disability, eventually leading to premature death. The most common NBIA disorder is pantothenate kinase-associated neurodegeneration (PKAN). TIRCON (Treat Iron-Related Childhood-Onset Neurodegeneration) is a research consortium comprising 13 partners from 8 countries and funded by the EU. Along with members of this consortium, the two ApoPharma sponsored studies were looking at the effect of deferiprone in patients with PKAN. These studies were conducted from 2011 to 2017, and reports are now being prepared for publication. Through a compassionate-use program, ApoPharma is continuing to provide deferiprone at no cost to patients who completed the studies.

For more information, please visit: www.tircon.eu